<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881110379509</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881110379509</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A [<sup>11</sup>C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lingford-Hughes</surname><given-names>Anne</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110379509">1</xref>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Reid</surname><given-names>Alastair G</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110379509">1</xref>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Myers</surname><given-names>James</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110379509">1</xref>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Feeney</surname><given-names>Adrian</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110379509">1</xref>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hammers</surname><given-names>Alexander</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Taylor</surname><given-names>Lindsay G</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110379509">1</xref>
<xref ref-type="aff" rid="aff3-0269881110379509">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rosso</surname><given-names>Lula</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Turkheimer</surname><given-names>Federico</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brooks</surname><given-names>David J</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
<xref ref-type="aff" rid="aff4-0269881110379509">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Grasby</surname><given-names>Paul</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110379509">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nutt</surname><given-names>David J</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110379509">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881110379509"><label>1</label>Psychopharmacology Unit, Dorothy Hodgkin Building, University of Bristol, Bristol, UK</aff>
<aff id="aff2-0269881110379509"><label>2</label>MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, UK</aff>
<aff id="aff3-0269881110379509"><label>3</label>University Hospitals Bristol NHS Foundation Trust, Bristol, UK</aff>
<aff id="aff4-0269881110379509"><label>4</label>Hammersmith Imanet Ltd, Hammersmith Hospital, London, UK</aff>
<author-notes>
<corresp id="corresp1-0269881110379509">Anne Lingford-Hughes, Neuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, Burlington Danes Building, Hammersmith Hospital Campus, 160 Du Cane Road, London, W12 0NN, UK Email: <email>anne.lingford-hughes@ic.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>2</issue>
<fpage>273</fpage>
<lpage>281</lpage>
<permissions>
<copyright-statement>© British Association for Psychopharmacology 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Preclinical evidence suggests the α5 subtype of the GABA-benzodiazepine receptor is involved in some of the actions of alcohol and in memory. The positron emission tomography (PET) tracer, [<sup>11</sup>C]Ro15 4513 shows relative selectivity in labelling the α5 subtype over the other GABA-benzodiazepine receptor subtypes in limbic regions of the brain. We used this tracer to investigate the distribution of α5 subtype availability in human alcohol dependence and its relationship to clinical variables. Abstinent (&gt;6 weeks) alcohol-dependent men and healthy male controls underwent an [<sup>11</sup>C]Ro15 4513 PET scan. We report [<sup>11</sup>C]Ro15 4513 brain uptake for 8 alcohol-dependent men and 11 healthy controls. We found a significant reduction in [<sup>11</sup>C]Ro15 4513 binding in the nucleus accumbens, parahippocampal gyri, right hippocampus and amygdala in the alcohol-dependent compared with the healthy control group. Levels of [<sup>11</sup>C]Ro15 4513 binding in both hippocampi were significantly and positively associated with performance on a delayed verbal memory task in the alcohol-dependent but not the control group. We speculate that the reduced limbic [<sup>11</sup>C]Ro15 4513 binding seen here results from the effects of alcohol, though we cannot currently distinguish whether they are compensatory in nature or evidence of brain toxicity.</p>
</abstract>
<kwd-group>
<kwd>Alcoholism</kwd>
<kwd>benzodiazepine</kwd>
<kwd>memory</kwd>
<kwd>PET</kwd>
<kwd>Ro15 4513</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881110379509" sec-type="intro">
<title>Introduction</title>
<p>The effects of alcohol on the GABA-benzodiazepine receptor system are complex. Most of the GABA<sub>A</sub> receptors in the brain contain α, β and γ subunits in a 2:2:1 stoichiometry (<xref ref-type="bibr" rid="bibr49-0269881110379509">Tretter et al., 1997</xref>). The α subunit is of particular importance in determining the pharmacology of the benzodiazepine type drugs and alcohol (<xref ref-type="bibr" rid="bibr23-0269881110379509">Krystal et al., 2006</xref>; <xref ref-type="bibr" rid="bibr38-0269881110379509">Rudolph and Mohler, 2004</xref>). Animal studies have clearly demonstrated differential effects depending on the subunit and region (<xref ref-type="bibr" rid="bibr18-0269881110379509">Grobin et al., 2000</xref>). Until recently we have not been able to probe the different subtypes in man in vivo. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies have shown that uptake of the non-subtype selective tracers, flumazenil and iomazenil, is reduced in alcoholics abstinent for at least 1 month (<xref ref-type="bibr" rid="bibr1-0269881110379509">Abi-Dargham et al., 1998</xref>; <xref ref-type="bibr" rid="bibr24-0269881110379509">Lingford-Hughes et al., 1998</xref>; <xref ref-type="bibr" rid="bibr42-0269881110379509">Staley et al., 2005</xref>). Differential effects of alcohol dependence on benzodiazepine receptor subtypes in man are suggested by a blunted effect on midazolam-induced sleep but no difference in beta-electroencephalograph (EEG) response compared with controls (<xref ref-type="bibr" rid="bibr26-0269881110379509">Lingford-Hughes et al., 2005</xref>).</p>
<p>We previously demonstrated that [<sup>11</sup>C]Ro15 4513 shows relative selectivity for the α5 subtype of the GABA-benzodiazepine receptor (<xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al., 2002</xref>), a finding since replicated (<xref ref-type="bibr" rid="bibr27-0269881110379509">Maeda et al., 2003</xref>). Unlike [<sup>11</sup>C]flumazenil, which shows similar levels of uptake in neocortex and limbic regions, the distribution of [<sup>11</sup>C]Ro15 4513 is characterized by increased uptake in the limbic regions including the hippocampus, anterior cingulate cortex and nucleus accumbens. High [<sup>11</sup>C]Ro15 4513 binding in the hippocampus is consistent with current theories about the role of the α5 subtype in memory – particularly hippocampal-dependent, explicit memory (<xref ref-type="bibr" rid="bibr39-0269881110379509">Savic et al., 2005</xref>). Indeed, we have shown that an inverse agonist at this subtype can reverse the memory-impairing effects of acute alcohol consumption (<xref ref-type="bibr" rid="bibr33-0269881110379509">Nutt et al., 2007</xref>). The α5 subtype has also been implicated in the reinforcing effects of alcohol, since α5 knockout mice consume less alcohol in self-administration paradigms (<xref ref-type="bibr" rid="bibr6-0269881110379509">Boehm et al., 2004</xref>; <xref ref-type="bibr" rid="bibr43-0269881110379509">Stephens et al., 2005</xref>) and an α5 inverse agonist reduces such intake in wild-type mice (<xref ref-type="bibr" rid="bibr43-0269881110379509">Stephens et al., 2005</xref>).</p>
<p>We hypothesized that [<sup>11</sup>C]Ro15 4513 would show a different pattern of binding in alcohol dependence to those reported for the non-selective tracers, [<sup>11</sup>C]flumazenil or [<sup>123</sup>I]iomazenil. We therefore compared [<sup>11</sup>C]Ro15 4513 binding in a group of alcohol-dependent individuals abstinent for at least a month with that in healthy controls to investigate the distribution of the α5 subtype of the GABA-benzodiazepine receptor system in alcohol dependence and its relationship with clinical variables.</p>
</sec>
<sec id="section2-0269881110379509" sec-type="materials|methods">
<title>Materials and methods</title>
<p>Abstinent male individuals who fulfilled DSM IV criteria for alcohol dependence were recruited from local alcohol outpatient treatment services. They had all been abstinent for at least 6 weeks and the average length of abstinence was 33.4 months (± 44.7 (SD), range 2–108 months; see <xref ref-type="table" rid="table1-0269881110379509">Table 1</xref>). This avoided the early withdrawal/abstinence phase when significant changes in blood flow and benzodiazepine receptor binding are reported which might confound comparisons (<xref ref-type="bibr" rid="bibr42-0269881110379509">Staley et al., 2005</xref>). The control group consisted of male individuals who had never fulfilled such criteria, i.e. were non-dependent alcohol drinkers and were recruited through colleagues and advertisements. Individuals with clinical evidence of hepatic, cognitive or neurological impairment or medical disorder were excluded. No individual had a previous or current history of psychosis.</p>
<table-wrap id="table1-0269881110379509" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic and clinical data</p>
</caption>
<graphic alternate-form-of="table1-0269881110379509" xlink:href="10.1177_0269881110379509-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th align="left">Clinical Variable</th>
<th align="left">Control</th>
<th align="left">Alcohol dependent</th>
</tr>
</thead>
<tbody align="left">
<tr>
<td>Age (yr)</td>
<td>43 ± 7</td>
<td>44 ± 7</td>
</tr>
<tr>
<td>Beck’s depression inventory</td>
<td>4.5 ± 4.4</td>
<td>10.9 ± 10.5</td>
</tr>
<tr>
<td>Spielberger – State anxiety</td>
<td>27.7 ± 7.2</td>
<td>35.5 ± 13.5</td>
</tr>
<tr>
<td>Spielberger – Trait anxiety</td>
<td>33.5 ± 11.6</td>
<td>37.25 ± 11.8</td>
</tr>
<tr>
<td>SADQ</td>
<td>2 ± 2</td>
<td>36 ± 18</td>
</tr>
<tr>
<td>Length of abstinence (months)</td>
<td>n/a</td>
<td>33.4 ± 44.7</td>
</tr>
<tr>
<td>Years of alcohol dependence</td>
<td>n/a</td>
<td>14.9 ± 5.3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881110379509">
<p>SADQ: Severity of Dependency Questionnaire.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Two alcohol-dependent individuals were receiving treatment with fluoxetine. We have previously shown that individuals taking antidepressants show no difference in their [<sup>11</sup>C]flumazenil binding compared with those not on antidepressants (<xref ref-type="bibr" rid="bibr26-0269881110379509">Lingford-Hughes et al., 2005</xref>), and given the small numbers here we were unable to conduct a formal analysis comparing these two individuals with the remaining six. No other prescribed psychotropic drugs were being currently taken, and exposure to benzodiazepines had not occurred for at least 6 weeks since detoxification in the alcohol-dependent group. Of the controls, two were smokers, three were ex-smokers and six were non-smokers compared with two smokers, five non-smokers and one ex-smoker in the alcohol-dependent group. Recreational or occasional use of illicit drugs (e.g. cannabis), but not dependency (DSM IV defined) was admissible. In the control group, five of the eleven had tried illicit drugs, and seven of the eight alcohol-dependent individuals; cannabis was most commonly tried, though only on a few occasions and/or when they were much younger. However, all were abstinent from illicit drugs during their period of abstinence from alcohol required for participation in this study.</p>
<p>All individuals were assessed for their severity of dependency (The Severity of Dependency Questionnaire (SADQ), <xref ref-type="bibr" rid="bibr45-0269881110379509">Stockwell et al., 1983</xref>). Anxiety and depression were assessed using the Beck Depression Inventory (BDI) (<xref ref-type="bibr" rid="bibr3-0269881110379509">Beck et al., 1961</xref>), and Spielberger State–Trait Anxiety Inventory (SSAI, STAI) (<xref ref-type="bibr" rid="bibr40-0269881110379509">Spielberger et al., 1970</xref>).</p>
<sec id="section3-0269881110379509">
<title>Neuropsychological battery</title>
<p>The neuropsychological battery used is fully described elsewhere (<xref ref-type="bibr" rid="bibr14-0269881110379509">Davies et al., 2005</xref>) and was compiled to include a range of tests, some of which were expected to be altered in alcohol dependence, that could be delivered easily using pencil and paper. Briefly, the following were completed on a different day, but within about a week, from the scan: 1. (a) Vocabulary, (b) Arithmetic, (c) Block design, (d) Picture arrangement and (e) Digit Symbol subtests of the Wechsler Adult Intelligence Scale (WAIS-R) (<xref ref-type="bibr" rid="bibr53-0269881110379509">Wechsler, 1981</xref>); 2. Verbal memory was tested with the Weschler Memory Scale: logical memory (immediate and 30-min delayed recall of two stories; <xref ref-type="bibr" rid="bibr54-0269881110379509">Wechsler, 1987</xref>); 3. Visuospatial memory was tested with the Rey-Osterrieth Complex Figure Test; 4. Trail Making Tests (Trail A and B) from the Halstead-Reitan Battery; 5. Verbal fluency using the ‘controlled oral word association’ test with letters F, A and S.</p>
</sec>
<sec id="section4-0269881110379509">
<title>[<sup>11</sup>C]Ro15 4513 PET</title>
<p>We followed the same protocol as described in <xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al. (2002)</xref>. [<sup>11</sup>C]Ro15 4513 was synthesized by <italic>N</italic>-methylation of the corresponding <italic>N</italic>-desmethyl derivative with [<sup>11</sup>C]iodomethane. The product was purified by reverse phase high-performance liquid chromatography (HPLC) on a column (Phenomenex Ultra-carb 7 ODS (30), 250 × 10 mm o.d.) eluted with MeCN/0.03M-MeCOONH<sub>4</sub>/AcOH (100/100/1 by vol.). The specific radioactivity was ∼14,000 MBq/µmol at end of synthesis.</p>
<p>[<sup>11</sup>C]Ro15 4513 scans were performed using an ECAT EXACT3D HR++ PET scanner (CTI/Siemens, Knoxville, TN, USA) with performance characteristics as described previously (<xref ref-type="bibr" rid="bibr41-0269881110379509">Spinks et al., 2000</xref>). Briefly, this scanner consists of six rings of standard detector blocks with 4.39 mm × 4.05 mm × 30 mm elements giving an axial field of view of 23.4 cm. A transmission scan was acquired before every emission using a single rotating photon point source of 150 MBq of <sup>137</sup>Cs for subsequent attenuation correction and scatter correction. The spatial resolution of the images reconstructed using the reprojection algorithm with the ramp and Colsher filters set to Nyquist frequency is close to isotropic: 5.1 mm (full width at half maximum [FWHM]) transaxially and 5.9 mm FWHM axially. A bolus injection of [<sup>11</sup>C]Ro15 4513 [370 MBq, ∼10 mCi] in ∼2 mL was administered through an intravenous cannula sited in the dominant antecubital fossa vein. Twenty dynamic frames (1 × 30, 4 × 15, 4 × 60, 2 × 150, 2 × 300, 7 × 600 s) of data were acquired in 3D mode over 90 min and produced images containing 78 contiguous slices. Blood sampling was carried out to produce a metabolite-corrected plasma input function (<xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al., 2002</xref>).</p>
</sec>
<sec id="section5-0269881110379509">
<title>Image analysis</title>
<p>Reconstructed [<sup>11</sup>C]Ro15 4513 images were analysed on a Sun SPARC workstation (Sun Microsystems, Mountain View, CA, USA) using Analyze AVW version 8.1 (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN; <xref ref-type="bibr" rid="bibr37-0269881110379509">Robb and Hanson, 1991</xref>), Matlab 6, 6.5 and SPM5 (available via <ext-link ext-link-type="uri" xlink:href="http://www.fil.ion.ucl.ac.uk/spm/">http://www.fil.ion.ucl.ac.uk/spm/</ext-link>).</p>
<p>Metabolite-corrected arterial plasma input functions were calibrated against discrete blood samples using a well counter cross-calibrated to the scanner. Parent plasma input functions were generated by multiplying the calibrated arterial radioactivity by the plasma-over-blood ratio and the parent fraction in plasma using Clickfit v1.66 in-house software in Matlab 6. Voxel-by-voxel parametric images of volume of distribution were produced using spectral analysis using parent plasma input functions (<xref ref-type="bibr" rid="bibr13-0269881110379509">Cunningham and Jones, 1993</xref>; <xref ref-type="bibr" rid="bibr50-0269881110379509">Turkheimer et al., 1994</xref>), implemented in in-house software.</p>
<p>Add-images were also created by summation of all 20 frames to provide the best possible anatomical PET data to be used for co-registration or normalization to anatomical data (magnetic resonance imaging, MRI).</p>
<p>In order to help define regions of interest, a structural MRI scan was obtained. All individuals were scanned using a Philips 1.5T Gyroscan Intera scanner. A T1-weighted protocol was used with the following parameters: 3D fast field echo mode, time to echo (TE) = 5 ms, repetition time (TR) = 10.6 ms, flip angle = 8.0°, to produce 130 coronal slices of 1.5 mm thickness. All MRIs were viewed by a clinical consultant radiologist and none were reported as having significant atrophy or abnormalities. Unfortunately, due to technical difficulties in the scan protocols and the ability to rescan only some individuals (since people moved away or some alcoholics had relapsed), only MRIs from 13 individuals (six healthy control and seven alcohol-dependent individuals) were successfully acquired and could be coregistered with PET add-images.</p>
<p>To overcome the lack of MRIs for some individuals and still be able to accurately define regions of interest (ROIs) using a maximum probability map (<xref ref-type="bibr" rid="bibr21-0269881110379509">Hammers et al., 2003</xref>), we generated an [<sup>11</sup>C]Ro15 4513 PET template from these 13 individuals for whom a PET and MRI scan was available according to the methodology in <xref ref-type="bibr" rid="bibr31-0269881110379509">Meyer et al. (1999)</xref>. To create the add-image template, individual add-images were coregistered to their corresponding MRI, and these MRIs were then normalized to Montreal Neurological Institute (MNI) space (International Consortium for Brain Mapping (ICBM)/Montreal Neurological Institute) using SPM5 ‘Unified Segmentation’. The coregistered add-images were normalized to MNI using the same deformation parameters, and a soft mean of all these images created a template for [<sup>11</sup>C]Ro15 4513 in MNI space. The warping of this template back to individual add-images allowed simultaneous warping of a maximum probability map further developed from <xref ref-type="bibr" rid="bibr21-0269881110379509">Hammers et al. (2003)</xref> to individual volume of distribution images. Prior to regional sampling, the goodness of fit of each object map to the individual brain was checked in Analyze 8.1. The ROI sampling was performed in Analyze 8.1 to obtain the mean <italic>V</italic><sub>T</sub> through all slices for all regions in the atlas.</p>
</sec>
<sec id="section6-0269881110379509">
<title>Statistical analysis</title>
<p>Statistical analyses were conducted using GraphPad Prism (version 4.02 for Windows, GraphPad Software, San Diego, CA, USA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">www.graphpad.com</ext-link>). A repeated measures two-way analysis of variance (ANOVA) with ROI and Group (alcohol-dependent versus controls) was used to compare [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> in alcohol-dependent individuals with that in controls. Results were corrected for multiple comparisons using a rigorous post-hoc correction for multivariate analyses (P-plot; <xref ref-type="bibr" rid="bibr51-0269881110379509">Turkheimer et al., 2001</xref>). For regions where we had an a priori hypothesis, (limbic regions involved in addiction: nucleus accumbens, anterior cingulate cortex, hippocampus, insula, and orbitofrontal cortex), a two-tailed Student’s <italic>t</italic>-test was used to compare mean [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> in alcohol-dependent individuals with that in controls. Variation of severity of dependency, length of abstinence, anxiety and depression ratings and performance on neuropsychological tasks in relation to regional <italic>V</italic><sub>T</sub> were tested with linear regressions.</p>
<p>Informed consent was obtained before participation in the study, which had been approved by the local Ethics Committees and by the UK Administration of Radioactive Substances Advisory Committee.</p>
</sec>
</sec>
<sec id="section7-0269881110379509" sec-type="results">
<title>Results</title>
<p>As we described previously, the highest [<sup>11</sup>C]Ro15 4513 volume of distribution (<italic>V</italic><sub>T</sub>) were found in limbic regions (see <xref ref-type="fig" rid="fig1-0269881110379509">Figure 1</xref>). The maximum probability map used in this study gave us greater accuracy in defining ROIs compared with the limited data-based regions manually drawn on PET images that were collected in the previously published study (<xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al., 2002</xref>). For instance in healthy volunteers, the highest <italic>V</italic><sub>T</sub> was seen in the nucleus accumbens (mean ± SD) (right: 11.25 ± 1.34; left: 11.07 ± 1.24), anterior cingulate cortex (right: 7.38 ± 0.75; left 7.08 ± 0.70), hippocampus (right: 7.52 ± 0.61; left: 7.5 ± 0.81) and amygdala (right: 7.04 ± 0.80; left: 6.89 ± 0.60).</p>
<fig id="fig1-0269881110379509" position="float">
<label>Figure 1.</label>
<caption>
<p>Levels of [<sup>11</sup>C]Ro15 4513 binding in brain regions in healthy controls and abstinent alcohol-dependent individuals. HC: hippocampus; temp ctx: temporal cortex; front ctx: frontal cortical regions; for complete list of abbreviations see <xref ref-type="bibr" rid="bibr19-0269881110379509">Gousias et al. (2008)</xref>.</p>
</caption>
<graphic xlink:href="10.1177_0269881110379509-fig1.tif"/>
</fig>
<sec id="section8-0269881110379509">
<title>Comparison between alcohol-dependent individuals and controls</title>
<p>A significant group effect (alcohol-dependent individual versus controls) was seen, with a lower mean <italic>V</italic><sub>T</sub> of the entire brain in alcoholics (<italic>F</italic> = 137.1; <italic>p</italic> &lt; 0.0001). There was no significant difference in metabolism of [<sup>11</sup>C]Ro 15 4513 between alcohol-dependent individuals and controls (<italic>p</italic> &gt; 0.05). Using the maximum probability map to define 73 regions, there was a significant interaction between region and group between regions (<italic>F</italic> = 172.4; <italic>p</italic> &lt; 0.0001), with alcohol-dependent individuals showing lower [<sup>11</sup>C]Ro 15 4513 binding levels in many but not all regions (see <xref ref-type="fig" rid="fig1-0269881110379509">Figure 1</xref>). After correcting for multiple comparisons using P plot, [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> were significantly lower in the alcohol-dependent group compared with controls in the nucleus accumbens (left: control: 11.07 ± 1.24 versus alcohol-dependent individuals: 9.95 ± 1.67, <italic>t</italic> = 4.18; <italic>p</italic> = 0.001; right: control: 11.25 ± 1.34 versus alcohol-dependent individuals 10.10 ± 1.55; <italic>t</italic> = 4.23; <italic>p</italic> = 0.001), parahippocampal gyri (left: control: 7.11 ± 0.77 versus alcohol-dependent individuals: 6.34 ± 0.91; <italic>t</italic> = 2.9; <italic>p</italic> = 0.01; right control: 6.81 ± 0.67 versus alcohol-dependent individuals 6.09 ± 0.72; <italic>t</italic> = 2.7; <italic>p</italic> = 0.02), right hippocampus (control: 7.52 ± 0.61 versus alcohol-dependent individuals 6.78 ± 0.9; <italic>t</italic> = 2.76; <italic>p</italic> = 0.02) and right amygdala (control: 7.04 ± 0.8 versus alcohol-dependent individual: 6.37 ± 0.81; <italic>t</italic> = 2.51; <italic>p</italic> = 0.03). We also compared the volume of the ROIs in the control and alcohol-dependent groups and found no significant differences (see <xref ref-type="fig" rid="fig2-0269881110379509">Figure 2</xref>). The effect of smoking status was also considered with no effect apparent in the data, but given the small numbers of smokers and ex-smokers no formal statistical analysis was performed.</p>
<fig id="fig2-0269881110379509" position="float">
<label>Figure 2.</label>
<caption>
<p>Volume of regions of interest from maximum probability map in healthy controls and abstinent alcohol-dependent individuals. See Figure 1 legend for description of abbreviations and regions.</p>
</caption>
<graphic xlink:href="10.1177_0269881110379509-fig2.tif"/>
</fig>
</sec>
<sec id="section9-0269881110379509">
<title>Correlations with clinical variables</title>
<p>No correlations were found between [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> and ratings of anxiety or depression (SSAI, STAI, BDI) both when considering them as a single group and within each separate group, for alcohol-dependent individuals and controls. In the alcohol-dependent individuals, [<sup>11</sup>C]Ro15 4513 binding did not correlate with length of abstinence, SADQ score nor age in any region. Given the suggested role for the hippocampal α5 subtype in memory, we specifically examined whether performance of the task most representative of hippocampal function in our battery, the delayed verbal recall of the Wechsler memory task, was associated with hippocampal Ro15 4513 <italic>V</italic><sub>T</sub>. In this task, individuals are read a story which they then have to re-tell followed by ‘delayed recall’ 30 min later, scoring points for each element remembered. We found a significant association between [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> and delayed recall in alcohol-dependent individuals (left hippocampus: <italic>r</italic><sup>2</sup> = 0.587; <italic>p</italic> = 0.027; right hippocampus: <italic>r</italic><sup>2</sup> = 0.747; <italic>p</italic> = 0.006) but not in controls (see <xref ref-type="fig" rid="fig3-0269881110379509">Figure 3</xref>). When we explored the relationship between [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> and delayed memory performance for other regions, significant correlations were also found in the right amygdala (<italic>r</italic><sup>2</sup> = 0.655; <italic>p</italic> = 0.015), right anterior cingulate cortex (<italic>r</italic><sup>2</sup> = 0.610; <italic>p</italic> = 0.022) and right superior frontal area (<italic>r</italic><sup>2</sup> = 0.632; <italic>p</italic> = 0.018) but not nucleus accumbens (right: <italic>r</italic><sup>2</sup> = 0.42; <italic>p</italic> = 0.08; left: <italic>r</italic><sup>2</sup> = 0.336; <italic>p</italic> = 0.132). We then explored whether there was any association between performance on all tests from the neuropsychological battery and [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> binding in alcohol-dependent individuals and in controls together and separately and found none. It is acknowledged that given the low numbers, these correlations should be interpreted with caution.</p>
<fig id="fig3-0269881110379509" position="float">
<label>Figure 3.</label>
<caption>
<p>Relationship between performance on delayed recall on Wechsler verbal memory task and [<sup>11</sup>C]Ro15 4513 binding (<italic>V</italic><sub>T</sub>) in the right and left hippocampi in healthy controls and abstinent alcohol-dependent individuals.</p>
</caption>
<graphic xlink:href="10.1177_0269881110379509-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-0269881110379509" sec-type="discussion">
<title>Discussion</title>
<p>In this first [<sup>11</sup>C]Ro15 4513 PET study of alcohol dependence, we have shown that there are globally reduced levels of [<sup>11</sup>C]Ro15 4513 <italic>V</italic><sub>T</sub> in abstinent alcohol-dependent individuals compared with controls which reach significance in the nucleus accumbens and right hippocampus. In these limbic regions, since [<sup>11</sup>C]Ro15 4513 shows relative selectivity for the α5 subtype (<xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al., 2002</xref>; <xref ref-type="bibr" rid="bibr27-0269881110379509">Maeda et al., 2003</xref>), this suggests that alcohol dependence is associated with reduced availability of the α5 subtype of the GABA-benzodiazepine receptor. We did not see any areas of increased [<sup>11</sup>C]Ro15 4513 binding in alcohol dependence. In addition, in alcohol-dependent individuals, but not controls, the level of [<sup>11</sup>C]Ro15 4513 binding in the hippocampus was positively associated with performance on a delayed verbal memory task.</p>
<p>Previous neuroimaging studies of abstinent alcohol-dependent individuals using non-selective tracers ([<sup>11</sup>C]flumazenil or [<sup>123</sup>I]iomazenil) have reported reductions in benzodiazepine receptor binding predominantly in frontal areas rather than in striatal or hippocampal regions as seen here (<xref ref-type="bibr" rid="bibr1-0269881110379509">Abi-Dargham et al., 1998</xref>; <xref ref-type="bibr" rid="bibr24-0269881110379509">Lingford-Hughes et al., 1998</xref>). We acknowledge the small sample size in each group, a consequence of the loss of the scanner; however, the findings in the alcohol-dependent group were consistent in that all showed this pattern of limbic, rather than cortical, reductions and in no region was an increase seen. One study reported increases in [<sup>123</sup>I]iomazenil binding within the first week of abstinence from alcohol in several brain areas, which returned to normal levels 4 weeks later (<xref ref-type="bibr" rid="bibr42-0269881110379509">Staley et al., 2005</xref>). Our alcohol-dependent individuals were abstinent for at least 6 weeks to avoid this time of change immediately after detoxification. We also found no apparent effect of smoking status on [<sup>11</sup>C]Ro15 4513 binding, which is consistent with <xref ref-type="bibr" rid="bibr42-0269881110379509">Staley et al., (2005)</xref> who reported at 4 weeks’ abstinence no difference between [<sup>123</sup>I]iomazenil binding in non-smokers and smokers.</p>
<p>We have previously shown that [<sup>11</sup>C]Ro15 4513 PET is an in vivo marker of the GABA-benzodiazepine receptor containing the α5 subtype in limbic structures (<xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al., 2002</xref>), supported by a subsequent study (<xref ref-type="bibr" rid="bibr27-0269881110379509">Maeda et al., 2003</xref>). Ro15 4513 has been shown to have a 10–15-fold higher affinity for the α5-containing subtype than the other benzodiazepine subtypes (<xref ref-type="bibr" rid="bibr20-0269881110379509">Hadingham et al., 1993</xref>). Our competition experiments with [<sup>11</sup>C]Ro15 4513 and compounds with relatively selective affinity for the α1 (zolpidem) or α5 (L655,708; RY80) subtype in animals, along with the reported distribution of α5 subunit protein (<xref ref-type="bibr" rid="bibr17-0269881110379509">Fritschy and Mohler, 1995</xref>), strongly suggest that [<sup>11</sup>C]Ro15 4513 PET is primarily a marker of the α5 subtype in limbic regions. It has been suggested that Ro15 4513 may be labelling the α4 subtype (<xref ref-type="bibr" rid="bibr52-0269881110379509">Wallner et al., 2006</xref>); however, the brain area with the highest level of α4 containing receptors, the thalamus, does not give a particularly high [<sup>11</sup>C]Ro15 4513 PET signal (<xref ref-type="bibr" rid="bibr25-0269881110379509">Lingford-Hughes et al., 2002</xref>, and <xref ref-type="fig" rid="fig1-0269881110379509">Figure 1</xref> herein), suggesting that this subtype does not contribute significantly to [<sup>11</sup>C]Ro15 4513 binding with PET.</p>
<p>The alcohol-dependent individuals were all healthy. We have recruited many similar individuals from outpatient services for previous studies and they have not shown any impairment of liver function that could affect metabolism of the tracer (<xref ref-type="bibr" rid="bibr24-0269881110379509">Lingford-Hughes et al., 1998</xref>, <xref ref-type="bibr" rid="bibr26-0269881110379509">2005</xref>). In addition we have found minimal brain atrophy and none in the temporal lobe or striatum in subjects with similar characteristics to those in this study (<xref ref-type="bibr" rid="bibr24-0269881110379509">Lingford-Hughes et al., 1998</xref>). Unfortunately, for technical reasons we did not have MRI structural scans of sufficient quality from all subjects in the alcohol-dependent group for full structural analysis. Nevertheless, we did not find a significant difference in whole-brain volume, nor were any differences in volumes of [<sup>11</sup>C]Ro15 4513 PET scans seen between the groups, using the maximum probability map to define ROIs. This would be against partial volume effects substantially contributing to the global or focal reductions in [<sup>11</sup>C]Ro15 4513 binding seen in the alcohol-dependent cohort.</p>
<p>Concerning the hippocampus and nucleus accumbens specifically, where we did see significant reductions in [<sup>11</sup>C]Ro15 4513 binding, structural imaging studies suggest that volume reductions are only present in those that are recently sober and not in those with longer periods such as in this study (<xref ref-type="bibr" rid="bibr2-0269881110379509">Agartz et al., 1999</xref>; <xref ref-type="bibr" rid="bibr5-0269881110379509">Bleich et al., 2003</xref>; <xref ref-type="bibr" rid="bibr4-0269881110379509">Beresford et al., 2006</xref>; <xref ref-type="bibr" rid="bibr30-0269881110379509">Mechtcheriakov et al., 2007</xref>; <xref ref-type="bibr" rid="bibr47-0269881110379509">Sullivan et al., 1995</xref>, <xref ref-type="bibr" rid="bibr46-0269881110379509">2005</xref>). The only exception is a study reporting reduced volume in right but not left nucleus accumbens and no reductions in the hipppocampi in alcoholics who had been sober for at least 4 weeks but most had been for several years (<xref ref-type="bibr" rid="bibr28-0269881110379509">Makris et al., 2008</xref>). We therefore suggest that atrophy is not likely to be a major contributor to the reduction in [<sup>11</sup>C]Ro15 4513 binding seen in the nucleus accumbens and hippocampus.</p>
<p>Recently the role of α5 subtype has begun to be characterized and there is evidence that it is involved in alcohol reward and memory. While overall only 5% of the brain’s GABA-A receptors contain the α5 subunit, they constitute approximately 25% of the GABA-A receptors in the hippocampus (<xref ref-type="bibr" rid="bibr17-0269881110379509">Fritschy and Mohler, 1995</xref>; <xref ref-type="bibr" rid="bibr35-0269881110379509">Pirker et al., 2000</xref>). They are localized primarily in extrasynaptic regions on cell bodies and apical dendrites of glutamatergic pyramidal neurons in the CA1 and CA3 hippocampal regions (<xref ref-type="bibr" rid="bibr7-0269881110379509">Brunig et al., 2002</xref>), where they mediate tonic inhibitory currents rather than being involved in transient synaptic neurotransmission (<xref ref-type="bibr" rid="bibr8-0269881110379509">Caraiscos et al., 2004</xref>).</p>
<p>Concerning a role in alcohol reward, in a two-bottle choice paradigm, male α5 knockout mice have shown less preference for alcohol and consumed less than their wild-type counterparts, while females showed no difference in preference but did consume less at higher concentrations (<xref ref-type="bibr" rid="bibr6-0269881110379509">Boehm et al., 2004</xref>; <xref ref-type="bibr" rid="bibr43-0269881110379509">Stephens et al., 2005</xref>). In a self-administration operant paradigm, i.e. where animals had to lever press to gain access to alcohol, female α5 knockout mice were no different to wild-type mice in their responding for alcohol (<xref ref-type="bibr" rid="bibr43-0269881110379509">Stephens et al., 2005</xref>). However, several studies have shown that inverse agonists at the α5 subtype reduced lever pressing for alcohol in rats (RY 023; RY 024; <xref ref-type="bibr" rid="bibr22-0269881110379509">June et al., 2001</xref>; <xref ref-type="bibr" rid="bibr29-0269881110379509">McKay et al., 2004</xref>) and mice (α5IA-II; <xref ref-type="bibr" rid="bibr43-0269881110379509">Stephens et al., 2005</xref>) in a similar way to Ro15 4513. Notably, RY 023 was only active in rats when injected into the hippocampus and was inactive in the ventral tegmental area or nucleus accumbens (<xref ref-type="bibr" rid="bibr22-0269881110379509">June et al., 2001</xref>). This is interesting given that in our previous PET study we were unable to see any [<sup>11</sup>C]Ro15 4513 binding in the striatum of rats, suggesting a lack of the α5 subtype in this region. Lastly, the α5 subtype has been shown to contribute to the discriminative effects of alcohol in squirrel monkeys (<xref ref-type="bibr" rid="bibr36-0269881110379509">Platt et al., 2005</xref>).</p>
<p>Taking all these preclinical studies together, while acknowledging some inconsistencies, lower α5 levels appear to be associated with reduced alcohol preference and alcohol-seeking. These studies were performed in non-tolerant animals and it is not clear how they translate to human alcohol dependence and this [<sup>11</sup>C]Ro15 4513 PET study. We report here lower [<sup>11</sup>C]Ro15 4513 levels in the nucleus accumbens which probably reflect lower levels of the α5 subtype. From the preclinical models we would expect such low levels to be associated with reduced preference and alcohol-seeking, so these lower levels could reflect an adaptive change in these individuals who were able to successfully abstain. It would be of interest to perform similar scans in a group of alcohol-dependent individuals still drinking. Alternatively, the lower [<sup>11</sup>C]Ro15 4513 binding might reflect adaptation of the α5 subtype after exposure to alcohol, perhaps compensating for increased tonic inhibition caused by alcohol. Finally, it might reflect brain toxic effects of alcohol use and/or withdrawal episodes.</p>
<p>Our finding of a positive relationship between memory performance and [<sup>11</sup>C]Ro15 4513 binding in the hippocampus is the opposite to what we expected from the preclinical literature, where models using α5 knockouts and inverse agonists have shown that low levels or reduced function of α5 receptors are associated with enhanced performance on hippocampal but not on non-hippocampal learning or anxiety tasks (<xref ref-type="bibr" rid="bibr10-0269881110379509">Cheng et al., 2006</xref>; <xref ref-type="bibr" rid="bibr11-0269881110379509">Collinson et al., 2002</xref>; <xref ref-type="bibr" rid="bibr12-0269881110379509">Crestani et al., 2002</xref>; <xref ref-type="bibr" rid="bibr15-0269881110379509">Dawson et al., 2006</xref>; <xref ref-type="bibr" rid="bibr44-0269881110379509">Sternfeld et al., 2004</xref>). We ourselves have recently reported that an α5 inverse agonist blocked alcohol-induced memory impairment on a hippocampal task in heavy social drinkers (<xref ref-type="bibr" rid="bibr33-0269881110379509">Nutt et al., 2007</xref>). However, these studies are investigating memory in healthy animals or individuals, and not those that are or have been alcohol dependent. It is likely that the memory performance of the individuals in the present study is a consequence of their alcohol consumption and recovery rather than a pre-existing trait. It is not clear how the higher α5 levels are associated with better memory performance, but may reflect improved hippocampal integrity or function as the alcoholics with low α5 binding performed worse than the controls on the task. Interestingly, in an animal model of Foetal Alcohol Syndrome, a single in utero exposure to ethanol resulted in offspring with reduced α5 binding and in adulthood, α5 binding was increased compared with controls and impaired hippocampal memory was also found (<xref ref-type="bibr" rid="bibr48-0269881110379509">Toso et al., 2006</xref>). We do not have any information regarding exposure of our participants to alcohol in utero.</p>
<p>The results from the preclinical literature about the effects of alcohol on expression of the α5 subunit are also not consistent. In rats, after 2 weeks of dietary ethanol no changes of α5 mRNA in the cerebral cortex were found (<xref ref-type="bibr" rid="bibr16-0269881110379509">Devaud et al., 1995</xref>); however, reduced α5 protein immunoreactivity was reported in the fronto-parietal cortex after 2 weeks of alcohol, but not at 4 and 12 weeks (<xref ref-type="bibr" rid="bibr9-0269881110379509">Charlton et al., 1997</xref>). However, there was a significant increase in α5 mRNA in the hippocampus after 12 weeks of ethanol, accompanied by a trend towards an increase in α5 protein subunit levels. An increase in [<sup>3</sup>H]Ro15 4513 binding has been reported in the rat cerebral cortex after 6 days’ exposure to alcohol, which had reduced to control levels 24 h after withdrawal from ethanol (<xref ref-type="bibr" rid="bibr32-0269881110379509">Mhatre et al., 1988</xref>). While [<sup>3</sup>H]Ro15 4513 binding was summarized as not increasing in the hippocampus, the data did show an increase during chronic ethanol exposure. <xref ref-type="bibr" rid="bibr34-0269881110379509">Pickering et al. (2007)</xref> examined the correlation between drinking and expression of mRNA for a number of receptors in rat prefrontal cortex and hippocampus and found that in the prefrontal cortex, but not in the hippocampus, GABA-benzodiazepine α5 (but not α1 or α3) was strongly correlated with alcohol consumption after operant training. However, these preclinical studies do not reflect the complexity of alcohol dependence in man, with its longer periods of alcohol exposure and recurrent episodes of withdrawal, making translating any results problematic.</p>
<p>Determining what is cause or consequence of alcohol consumption is impossible to tease out from cross-sectional neuroimaging studies. <xref ref-type="bibr" rid="bibr24-0269881110379509">Lingford-Hughes et al. (1998)</xref> reported that severity of dependence and total lifetime amount of alcohol consumed were associated with a reduction in [<sup>123</sup>I]iomazenil binding, whereas in agreement with <xref ref-type="bibr" rid="bibr1-0269881110379509">Abi-Dargham et al. (1998)</xref>, length of dependency or abstinence were not. In the current study no significant relationship was apparent with any clinical variables.</p>
<p>In summary, we have shown reduced [<sup>11</sup>C]Ro15 4513 binding, most prominently and significantly in the nucleus accumbens and hippocampus of abstinent alcohol-dependent individuals compared with healthy volunteers. This pattern is different from the reductions in benzodiazepine receptors detected with [<sup>11</sup>C]flumazenil PET or [<sup>123</sup>I]iomazenil SPECT, where reductions are seen predominantly in the frontal cortex. This difference may reflect changes in alcohol dependence of the α1 subtype labelled by [<sup>11</sup>C]flumazenil compared with those of the α5 labelled by [<sup>11</sup>C]Ro15 4513. In addition, we have shown a significant positive relationship between a hippocampal memory task, delayed verbal memory, and the level of [<sup>11</sup>C]Ro15 4513 binding in the hippocampus. Preclinical studies suggest an important role for the α5 subtype, with low levels or function associated with reduced alcohol reinforcement and seeking and better memory performance – the opposite of what we have found here in alcohol-dependent men. We suggest that the low [<sup>11</sup>C]Ro15 4513 levels are therefore more likely to be a consequence of their drinking rather than underlying vulnerability. Such low levels of α5 subtype may reflect enduring alterations in brain inhibitory function that could predispose to relapse, or alternatively maintain remission. However, in those with preserved α5 receptor levels, memory function was not impaired. Further studies on currently drinking alcohol-dependent individuals and those with familial or other vulnerability factors are now indicated.</p>
</sec>
</body>
<back>
<sec id="section11-0269881110379509">
<title>Funding</title>
<p>The study was funded by a Medical Research Council programme grant.</p>
</sec>
<ack>
<p>This work was conducted in collaboration with Imanet, GE Healthcare.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abi-Dargham</surname><given-names>A</given-names></name>
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Anjilvel</surname><given-names>S</given-names></name>
<name><surname>Scanley</surname><given-names>BE</given-names></name>
<name><surname>Zoghbi</surname><given-names>S</given-names></name>
<name><surname>Baldwin</surname><given-names>RM</given-names></name><etal/>
</person-group> (<year>1998</year>) <article-title>Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil</article-title>. <source>Am J Psychiatry</source> <volume>155</volume>: <fpage>1550</fpage>–<lpage>1555</lpage>.</citation>
</ref>
<ref id="bibr2-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agartz</surname><given-names>I</given-names></name>
<name><surname>Momenan</surname><given-names>R</given-names></name>
<name><surname>Rawlings</surname><given-names>RR</given-names></name>
<name><surname>Kerich</surname><given-names>MJ</given-names></name>
<name><surname>Hommer</surname><given-names>DW</given-names></name>
</person-group> (<year>1999</year>) <article-title>Hippocampal volume in patients with alcohol dependence</article-title>. <source>Arch Gen Psychiatry</source> <volume>56</volume>: <fpage>356</fpage>–<lpage>363</lpage>.</citation>
</ref>
<ref id="bibr3-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beck</surname><given-names>AT</given-names></name>
<name><surname>Ward</surname><given-names>CH</given-names></name>
<name><surname>Mendelson</surname><given-names>M</given-names></name>
<name><surname>Mock</surname><given-names>JE</given-names></name>
<name><surname>Erbaugh</surname><given-names>J</given-names></name>
</person-group> (<year>1961</year>) <article-title>An inventory for measuring depression</article-title>. <source>Arch Gen Psychiatry</source> <volume>4</volume>: <fpage>561</fpage>–<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr4-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beresford</surname><given-names>TP</given-names></name>
<name><surname>Arciniegas</surname><given-names>DB</given-names></name>
<name><surname>Alfers</surname><given-names>J</given-names></name>
<name><surname>Clapp</surname><given-names>L</given-names></name>
<name><surname>Martin</surname><given-names>B</given-names></name>
<name><surname>Du</surname><given-names>Y</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Hippocampus volume loss due to chronic heavy drinking</article-title>. <source>Alcohol Clin Exp Res</source> <volume>30</volume>: <fpage>1866</fpage>–<lpage>1870</lpage>.</citation>
</ref>
<ref id="bibr5-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bleich</surname><given-names>S</given-names></name>
<name><surname>Sperling</surname><given-names>W</given-names></name>
<name><surname>Degner</surname><given-names>D</given-names></name>
<name><surname>Graesel</surname><given-names>E</given-names></name>
<name><surname>Bleich</surname><given-names>K</given-names></name>
<name><surname>Wilhelm</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2003</year>) <article-title>Lack of association between hippocampal volume reduction and first-onset alcohol withdrawal seizure. A volumetric MRI study</article-title>. <source>Alcohol Alcohol</source> <volume>38</volume>: <fpage>40</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr6-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boehm</surname><given-names>SL</given-names></name>
<name><surname>Ponomarev</surname><given-names>I</given-names></name>
<name><surname>Jennings</surname><given-names>AW</given-names></name>
<name><surname>Whiting</surname><given-names>PJ</given-names></name>
<name><surname>Rosahl</surname><given-names>TW</given-names></name>
<name><surname>Garrett</surname><given-names>EM</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Gamma-Aminobutyric acid A receptor subunit mutant mice: new perspectives on alcohol actions</article-title>. <source>Biochem Pharmacol</source> <volume>68</volume>: <fpage>1581</fpage>–<lpage>1602</lpage>.</citation>
</ref>
<ref id="bibr7-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunig</surname><given-names>I</given-names></name>
<name><surname>Scotti</surname><given-names>E</given-names></name>
<name><surname>Sidler</surname><given-names>C</given-names></name>
<name><surname>Fritschy</surname><given-names>JM</given-names></name>
</person-group> (<year>2002</year>) <article-title>Intact sorting, targeting, and clustering of gamma-aminobutyric acid A receptor subtypes in hippocampal neurons in vitro</article-title>. <source>J Comp Neurol</source> <volume>443</volume>: <fpage>43</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr8-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caraiscos</surname><given-names>VB</given-names></name>
<name><surname>Elliott</surname><given-names>EM</given-names></name>
<name><surname>You</surname><given-names>T</given-names></name>
<name><surname>Cheng</surname><given-names>VY</given-names></name>
<name><surname>Belelli</surname><given-names>D</given-names></name>
<name><surname>Newell</surname><given-names>JG</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>101</volume>: <fpage>3662</fpage>–<lpage>3667</lpage>.</citation>
</ref>
<ref id="bibr9-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charlton</surname><given-names>ME</given-names></name>
<name><surname>Sweetnam</surname><given-names>PM</given-names></name>
<name><surname>Fitzgerald</surname><given-names>LW</given-names></name>
<name><surname>Terwilliger</surname><given-names>RZ</given-names></name>
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
<name><surname>Duman</surname><given-names>RS</given-names></name>
</person-group> (<year>1997</year>) <article-title>Chronic ethanol administration regulates the expression of GABAA receptor alpha 1 and alpha 5 subunits in the ventral tegmental area and hippocampus</article-title>. <source>J Neurochem</source> <volume>68</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr10-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>VY</given-names></name>
<name><surname>Martin</surname><given-names>LJ</given-names></name>
<name><surname>Elliott</surname><given-names>EM</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
<name><surname>Mount</surname><given-names>HT</given-names></name>
<name><surname>Taverna</surname><given-names>FA</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate</article-title>. <source>J Neurosci</source> <volume>26</volume>: <fpage>3713</fpage>–<lpage>3720</lpage>.</citation>
</ref>
<ref id="bibr11-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collinson</surname><given-names>N</given-names></name>
<name><surname>Kuenzi</surname><given-names>FM</given-names></name>
<name><surname>Jarolimek</surname><given-names>W</given-names></name>
<name><surname>Maubach</surname><given-names>KA</given-names></name>
<name><surname>Cothliff</surname><given-names>R</given-names></name>
<name><surname>Sur</surname><given-names>C</given-names></name><etal/>
</person-group> (<year>2002</year>) <article-title>Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor</article-title>. <source>J Neurosci</source> <volume>22</volume>: <fpage>5572</fpage>–<lpage>5580</lpage>.</citation>
</ref>
<ref id="bibr12-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crestani</surname><given-names>F</given-names></name>
<name><surname>Keist</surname><given-names>R</given-names></name>
<name><surname>Fritschy</surname><given-names>JM</given-names></name>
<name><surname>Benke</surname><given-names>D</given-names></name>
<name><surname>Vogt</surname><given-names>K</given-names></name>
<name><surname>Prut</surname><given-names>L</given-names></name><etal/>
</person-group> (<year>2002</year>) <article-title>Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>99</volume>: <fpage>8980</fpage>–<lpage>8985</lpage>.</citation>
</ref>
<ref id="bibr13-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cunningham</surname><given-names>VJ</given-names></name>
<name><surname>Jones</surname><given-names>T</given-names></name>
</person-group> (<year>1993</year>) <article-title>Spectral analysis of dynamic PET studies</article-title>. <source>J Cerebr Blood Flow Metab</source> <volume>13</volume>: <fpage>15</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr14-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>SJC</given-names></name>
<name><surname>Pandit</surname><given-names>S</given-names></name>
<name><surname>Feeney</surname><given-names>A</given-names></name>
<name><surname>Stephenson</surname><given-names>B</given-names></name>
<name><surname>Kerwin</surname><given-names>R</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>Is there cognitive impairment in clinically ‘healthy’ abstinent alcohol dependence?</article-title> <source>Alcohol Alcohol</source> <volume>40</volume>: <fpage>498</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr15-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>GR</given-names></name>
<name><surname>Maubach</surname><given-names>KA</given-names></name>
<name><surname>Collinson</surname><given-names>N</given-names></name>
<name><surname>Cobain</surname><given-names>M</given-names></name>
<name><surname>Everitt</surname><given-names>BJ</given-names></name>
<name><surname>Macleod</surname><given-names>AM</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition</article-title>. <source>J Pharmacol Exp Ther</source> <volume>316</volume>: <fpage>1335</fpage>–<lpage>1345</lpage>.</citation>
</ref>
<ref id="bibr16-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Devaud</surname><given-names>LL</given-names></name>
<name><surname>Smith</surname><given-names>FD</given-names></name>
<name><surname>Grayson</surname><given-names>DR</given-names></name>
<name><surname>Morrow</surname><given-names>AL</given-names></name>
</person-group> (<year>1995</year>) <article-title>Chronic ethanol consumption differentially alters the expression of gamma-aminobutyric acidA receptor subunit mRNAs in rat cerebral cortex: competitive, quantitative reverse transcriptase-polymerase chain reaction analysis</article-title>. <source>Mol Pharmacol</source> <volume>48</volume>: <fpage>861</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr17-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fritschy</surname><given-names>JM</given-names></name>
<name><surname>Mohler</surname><given-names>H</given-names></name>
</person-group> (<year>1995</year>) <article-title>GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits</article-title>. <source>J Comp Neurol</source> <volume>359</volume>: <fpage>154</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr18-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grobin</surname><given-names>AC</given-names></name>
<name><surname>Papadeas</surname><given-names>ST</given-names></name>
<name><surname>Morrow</surname><given-names>AL</given-names></name>
</person-group> (<year>2000</year>) <article-title>Regional variations in the effects of chronic ethanol administration on GABA(A) receptor expression: potential mechanisms</article-title>. <source>Neurochem Int</source> <volume>37</volume>: <fpage>453</fpage>–<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr19-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gousias</surname><given-names>IS</given-names></name>
<name><surname>Rueckert</surname><given-names>D</given-names></name>
<name><surname>Heckemann</surname><given-names>RA</given-names></name>
<name><surname>Dyet</surname><given-names>LE</given-names></name>
<name><surname>Boardman</surname><given-names>JP</given-names></name>
<name><surname>Edwards</surname><given-names>AD</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest</article-title>. <source>Neuroimage</source> <volume>40</volume>: <fpage>672</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr20-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hadingham</surname><given-names>KL</given-names></name>
<name><surname>Wingrove</surname><given-names>P</given-names></name>
<name><surname>Le</surname></name>
<name><surname>Bourdelles</surname><given-names>B</given-names></name>
<name><surname>Palmer</surname><given-names>KJ</given-names></name>
<name><surname>Ragan</surname><given-names>CI</given-names></name>
<name><surname>Whiting</surname><given-names>PJ</given-names></name>
</person-group> (<year>1993</year>) <article-title>Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors</article-title>. <source>Mol Pharmacol</source> <volume>43</volume>: <fpage>970</fpage>–<lpage>975</lpage>.</citation>
</ref>
<ref id="bibr21-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hammers</surname><given-names>A</given-names></name>
<name><surname>Allom</surname><given-names>R</given-names></name>
<name><surname>Koepp</surname><given-names>MJ</given-names></name>
<name><surname>Free</surname><given-names>SL</given-names></name>
<name><surname>Myers</surname><given-names>R</given-names></name>
<name><surname>Lemieux</surname><given-names>L</given-names></name><etal/>
</person-group> (<year>2003</year>) <article-title>Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe</article-title>. <source>Hum Brain Mapp</source> <volume>19</volume>: <fpage>224</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr22-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>June</surname><given-names>HL</given-names></name>
<name><surname>Harvey</surname><given-names>SC</given-names></name>
<name><surname>Foster</surname><given-names>KL</given-names></name>
<name><surname>McKay</surname><given-names>PF</given-names></name>
<name><surname>Cummings</surname><given-names>R</given-names></name>
<name><surname>Garcia</surname><given-names>M</given-names></name><etal/>
</person-group> (<year>2001</year>) <article-title>GABA(A) receptors containing (alpha)5 subunits in the CA1 and CA3 hippocampal fields regulate ethanol-motivated behaviors: an extended ethanol reward circuitry</article-title>. <source>J Neurosci</source> <volume>21</volume>: <fpage>2166</fpage>–<lpage>2177</lpage>.</citation>
</ref>
<ref id="bibr23-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Staley</surname><given-names>J</given-names></name>
<name><surname>Mason</surname><given-names>G</given-names></name>
<name><surname>Petrakis</surname><given-names>IL</given-names></name>
<name><surname>Kaufman</surname><given-names>J</given-names></name>
<name><surname>Harris</surname><given-names>RA</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment</article-title>. <source>Arch Gen Psychiatry</source> <volume>63</volume>: <fpage>957</fpage>–<lpage>968</lpage>.</citation>
</ref>
<ref id="bibr24-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lingford-Hughes</surname><given-names>AR</given-names></name>
<name><surname>Acton</surname><given-names>PD</given-names></name>
<name><surname>Gacinovic</surname><given-names>S</given-names></name>
<name><surname>Suckling</surname><given-names>J</given-names></name>
<name><surname>Busatto</surname><given-names>GF</given-names></name>
<name><surname>Boddington</surname><given-names>SJA</given-names></name><etal/>
</person-group> (<year>1998</year>) <article-title>Reduced levels of the GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy</article-title>. <source>Br J Psychiatry</source> <volume>173</volume>: <fpage>16</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr25-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lingford-Hughes</surname><given-names>A</given-names></name>
<name><surname>Hume</surname><given-names>SP</given-names></name>
<name><surname>Feeney</surname><given-names>A</given-names></name>
<name><surname>Hirani</surname><given-names>E</given-names></name>
<name><surname>Osman</surname><given-names>S</given-names></name>
<name><surname>Cunningham</surname><given-names>VJ</given-names></name><etal/>
</person-group> (<year>2002</year>) <article-title>Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [<sup>11</sup>C]Ro15 4513 positron emission tomography</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>22</volume>: <fpage>878</fpage>–<lpage>889</lpage>.</citation>
</ref>
<ref id="bibr26-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lingford-Hughes</surname><given-names>AR</given-names></name>
<name><surname>Wilson</surname><given-names>SJ</given-names></name>
<name><surname>Cunningham</surname><given-names>VJ</given-names></name>
<name><surname>Feeney</surname><given-names>A</given-names></name>
<name><surname>Stevenson</surname><given-names>B</given-names></name>
<name><surname>Brooks</surname><given-names>DJ</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>GABA-benzodiazepine receptor function in alcohol dependence: a combined <sup>11</sup>C-flumazenil PET and pharmacodynamic study</article-title>. <source>Psychopharmacology</source> <volume>180</volume>: <fpage>595</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr27-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>J</given-names></name>
<name><surname>Suhara</surname><given-names>T</given-names></name>
<name><surname>Kawabe</surname><given-names>K</given-names></name>
<name><surname>Okauchi</surname><given-names>T</given-names></name>
<name><surname>Obayashi</surname><given-names>S</given-names></name>
<name><surname>Hojo</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2003</year>) <article-title>Visualization of a5 subunit of GABAA/benzodiazepine receptor by [<sup>11</sup>C]Ro15-4513 using positron emission tomography</article-title>. <source>Synapse</source> <volume>47</volume>: <fpage>200</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr28-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Makris</surname><given-names>N</given-names></name>
<name><surname>Oscar-Berman</surname><given-names>M</given-names></name>
<name><surname>Jaffin</surname><given-names>SK</given-names></name>
<name><surname>Hodge</surname><given-names>SM</given-names></name>
<name><surname>Kennedy</surname><given-names>DN</given-names></name>
<name><surname>Caviness</surname><given-names>VS</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Decreased volume of the brain reward system in alcoholism</article-title>. <source>Biol Psychiatry</source> <volume>64</volume>: <fpage>192</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr29-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKay</surname><given-names>PF</given-names></name>
<name><surname>Foster</surname><given-names>KL</given-names></name>
<name><surname>Mason</surname><given-names>D</given-names></name>
<name><surname>Cummings</surname><given-names>R</given-names></name>
<name><surname>Garcia</surname><given-names>M</given-names></name>
<name><surname>Williams</surname><given-names>LS</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>A high affinity ligand for GABAA-receptor containing alpha5 subunit antagonizes ethanol’s neurobehavioural effects in Long-Evans rats</article-title>. <source>Psychopharmacology</source> <volume>172</volume>: <fpage>455</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr30-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mechtcheriakov</surname><given-names>S</given-names></name>
<name><surname>Brenneis</surname><given-names>C</given-names></name>
<name><surname>Egger</surname><given-names>K</given-names></name>
<name><surname>Koppelstaetter</surname><given-names>F</given-names></name>
<name><surname>Schocke</surname><given-names>M</given-names></name>
<name><surname>Marksteiner</surname><given-names>J</given-names></name>
</person-group> (<year>2007</year>) <article-title>A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>78</volume>: <fpage>610</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr31-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>JH</given-names></name>
<name><surname>Gunn</surname><given-names>RN</given-names></name>
<name><surname>Myers</surname><given-names>R</given-names></name>
<name><surname>Grasby</surname><given-names>PM</given-names></name>
</person-group> (<year>1999</year>) <article-title>Assessment of spatial normalization of PET ligand images using ligand-specific templates</article-title>. <source>Neuroimage</source> <volume>9</volume>: <fpage>545</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr32-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mhatre</surname><given-names>M</given-names></name>
<name><surname>Mehta</surname><given-names>AK</given-names></name>
<name><surname>Ticku</surname><given-names>MK</given-names></name>
</person-group> (<year>1988</year>) <article-title>Chronic ethanol administration increases the binding of the benzodiazepine inverse agonist and alcohol antagonist [3H]RO15-4513 in rat brain</article-title>. <source>Eur J Pharmacol</source> <volume>153</volume>: <fpage>141</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr33-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<name><surname>Besson</surname><given-names>M</given-names></name>
<name><surname>Wilson</surname><given-names>SJ</given-names></name>
<name><surname>Dawson</surname><given-names>GR</given-names></name>
<name><surname>Lingford-Hughes</surname><given-names>AR</given-names></name>
</person-group> (<year>2007</year>) <article-title>Selective blockade of alcohol’s amnestic actions by an α5 subtype- benzodiazepine receptor inverse agonist</article-title>. <source>Neuropharmacology</source> <volume>53</volume>: <fpage>810</fpage>–<lpage>820</lpage>.</citation>
</ref>
<ref id="bibr34-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pickering</surname><given-names>C</given-names></name>
<name><surname>Avesson</surname><given-names>L</given-names></name>
<name><surname>Lindblom</surname><given-names>J</given-names></name>
<name><surname>Liljequist</surname><given-names>S</given-names></name>
<name><surname>Schiöth</surname><given-names>HB</given-names></name>
</person-group> (<year>2007</year>) <article-title>Identification of neurotransmitter receptor genes involved in alcohol self-administration in the rat prefrontal cortex, hippocampus and amygdala</article-title>. <source>Prog Neuropsychopharm Biol Psych</source> <volume>31</volume>: <fpage>53</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr35-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pirker</surname><given-names>S</given-names></name>
<name><surname>Schwarzer</surname><given-names>C</given-names></name>
<name><surname>Wieselthaler</surname><given-names>A</given-names></name>
<name><surname>Sieghart</surname><given-names>W</given-names></name>
<name><surname>Sperk</surname><given-names>G</given-names></name>
</person-group> (<year>2000</year>) <article-title>GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain</article-title>. <source>Neuroscience</source> <volume>101</volume>: <fpage>815</fpage>–<lpage>850</lpage>.</citation>
</ref>
<ref id="bibr36-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Platt</surname><given-names>DM</given-names></name>
<name><surname>Duggan</surname><given-names>A</given-names></name>
<name><surname>Spealman</surname><given-names>RD</given-names></name>
<name><surname>Cook</surname><given-names>JM</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Yin</surname><given-names>W</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>Contribution of alpha 1GABAA and alpha 5GABAA receptor subtypes to the discriminative stimulus effects of ethanol in squirrel monkeys</article-title>. <source>J Pharmacol Exp Ther</source> <volume>313</volume>: <fpage>658</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr37-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robb</surname><given-names>RA</given-names></name>
<name><surname>Hanson</surname><given-names>DP</given-names></name>
</person-group> (<year>1991</year>) <article-title>A software system for interactive and quantitative visualization of multidimensional biomedical images</article-title>. <source>Australas Phys Eng Sci Med</source> <volume>14</volume>: <fpage>9</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr38-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudolph</surname><given-names>U</given-names></name>
<name><surname>Mohler</surname><given-names>H</given-names></name>
</person-group> (<year>2004</year>) <article-title>Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics</article-title>. <source>Annu Rev Pharmacol Toxicol</source> <volume>44</volume>: <fpage>475</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr39-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savic</surname><given-names>MM</given-names></name>
<name><surname>Obradovic</surname><given-names>DI</given-names></name>
<name><surname>Ugrei</surname><given-names>ND</given-names></name>
<name><surname>Bokonji</surname><given-names>DR</given-names></name>
</person-group> (<year>2005</year>) <article-title>Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes</article-title>. <source>Neural Plast</source> <volume>12</volume>: <fpage>289</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr40-0269881110379509">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Spielberger</surname><given-names>C</given-names></name>
<name><surname>Gorsuch</surname><given-names>RL</given-names></name>
<name><surname>Lushene</surname><given-names>RE</given-names></name>
</person-group> (<year>1970</year>) <source>Manual for the state-trait anxiety inventory</source>. <publisher-loc>Palo Alto</publisher-loc>: <publisher-name>Consulting Psychologist Press</publisher-name>.</citation>
</ref>
<ref id="bibr41-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spinks</surname><given-names>TJ</given-names></name>
<name><surname>Jones</surname><given-names>T</given-names></name>
<name><surname>Bloomfield</surname><given-names>PM</given-names></name>
<name><surname>Bailey</surname><given-names>DL</given-names></name>
<name><surname>Miller</surname><given-names>M</given-names></name>
<name><surname>Hogg</surname><given-names>D</given-names></name><etal/>
</person-group> (<year>2000</year>) <article-title>Physical characteristics of the ECAT EXACT3D positron tomograph</article-title>. <source>Phys Med Biol</source> <volume>45</volume>: <fpage>2601</fpage>–<lpage>2618</lpage>.</citation>
</ref>
<ref id="bibr42-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Staley</surname><given-names>JK</given-names></name>
<name><surname>Gottschalk</surname><given-names>C</given-names></name>
<name><surname>Petrakis</surname><given-names>IL</given-names></name>
<name><surname>Gueorguieva</surname><given-names>R</given-names></name>
<name><surname>O’Malley</surname><given-names>S</given-names></name>
<name><surname>Baldwin</surname><given-names>R</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking</article-title>. <source>Arch Gen Psychiatry</source> <volume>62</volume>: <fpage>877</fpage>–<lpage>888</lpage>.</citation>
</ref>
<ref id="bibr43-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stephens</surname><given-names>DN</given-names></name>
<name><surname>Pistovcakova</surname><given-names>J</given-names></name>
<name><surname>Worthing</surname><given-names>L</given-names></name>
<name><surname>Atack</surname><given-names>JR</given-names></name>
<name><surname>Dawson</surname><given-names>GR</given-names></name>
</person-group> (<year>2005</year>) <article-title>Role of GABAA alpha5-containing receptors in ethanol reward: the effects of targeted gene deletion, and a selective inverse agonist</article-title>. <source>Eur J Pharmacol</source> <volume>526</volume>: <fpage>240</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr44-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sternfeld</surname><given-names>F</given-names></name>
<name><surname>Carling</surname><given-names>RW</given-names></name>
<name><surname>Jelley</surname><given-names>RA</given-names></name>
<name><surname>Ladduwahetty</surname><given-names>T</given-names></name>
<name><surname>Merchant</surname><given-names>KJ</given-names></name>
<name><surname>Moore</surname><given-names>KW</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers</article-title>. <source>J Med Chem</source> <volume>47</volume>: <fpage>2176</fpage>–<lpage>2179</lpage>.</citation>
</ref>
<ref id="bibr45-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stockwell</surname><given-names>T</given-names></name>
<name><surname>Murphy</surname><given-names>D</given-names></name>
<name><surname>Hodgson</surname><given-names>R</given-names></name>
</person-group> (<year>1983</year>) <article-title>The severity of alcohol dependence questionnaire: its use, reliability and validity</article-title>. <source>Br J Addict</source> <volume>78</volume>: <fpage>145</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr46-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>EV</given-names></name>
<name><surname>Deshmukh</surname><given-names>A</given-names></name>
<name><surname>De Rosa</surname><given-names>E</given-names></name>
<name><surname>Rosenbloom</surname><given-names>MJ</given-names></name>
<name><surname>Pfefferbaum</surname><given-names>A</given-names></name>
</person-group> (<year>2005</year>) <article-title>Striatal and forebrain nuclei volumes: contribution to motor function and working memory deficits in alcoholism</article-title>. <source>Biol Psychiatry</source> <volume>57</volume>: <fpage>768</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr47-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>EV</given-names></name>
<name><surname>Marsh</surname><given-names>L</given-names></name>
<name><surname>Mathalon</surname><given-names>DH</given-names></name>
<name><surname>Lim</surname><given-names>KO</given-names></name>
<name><surname>Pfefferbaum</surname><given-names>A</given-names></name>
</person-group> (<year>1995</year>) <article-title>Anterior hippocampal volume deficits in nonamnesic, aging chronic alcoholics</article-title>. <source>Alcohol Clin Exp Res</source> <volume>19</volume>: <fpage>110</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr48-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toso</surname><given-names>L</given-names></name>
<name><surname>Roberson</surname><given-names>R</given-names></name>
<name><surname>Woodard</surname><given-names>J</given-names></name>
<name><surname>Abebe</surname><given-names>D</given-names></name>
<name><surname>Spong</surname><given-names>CY</given-names></name>
</person-group> (<year>2006</year>) <article-title>Prenatal alcohol exposure alters GABA(A)alpha5 expression: a mechanism of alcohol-induced learning dysfunction</article-title>. <source>Am J Obstet Gynecol</source> <volume>195</volume>: <fpage>522</fpage>–<lpage>527</lpage>.</citation>
</ref>
<ref id="bibr49-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tretter</surname><given-names>V</given-names></name>
<name><surname>Ehya</surname><given-names>N</given-names></name>
<name><surname>Fuchs</surname><given-names>K</given-names></name>
<name><surname>Sieghart</surname><given-names>W</given-names></name>
</person-group> (<year>1997</year>) <article-title>Stoichiometry and assembly of a recombinant GABA<sub>A</sub> receptor subtype</article-title>. <source>J Neurosci</source> <volume>17</volume>: <fpage>2728</fpage>–<lpage>2737</lpage>.</citation>
</ref>
<ref id="bibr50-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turkheimer</surname><given-names>F</given-names></name>
<name><surname>Moresco</surname><given-names>RM</given-names></name>
<name><surname>Lucignani</surname><given-names>G</given-names></name>
<name><surname>Sokoloff</surname><given-names>L</given-names></name>
<name><surname>Fazio</surname><given-names>F</given-names></name>
<name><surname>Schmidt</surname><given-names>K</given-names></name>
</person-group> (<year>1994</year>) <article-title>The use of spectral analysis to determine regional cerebral glucose utilization with positron emission tomography and [18F]fluorodeoxyglucose: theory, implementation, and optimization procedures</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>14</volume>: <fpage>406</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr51-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turkheimer</surname><given-names>FE</given-names></name>
<name><surname>Smith</surname><given-names>CB</given-names></name>
<name><surname>Schmidt</surname><given-names>K</given-names></name>
</person-group> (<year>2001</year>) <article-title>Estimation of the number of “true” null hypotheses in multivariate analysis of neuroimaging data</article-title>. <source>Neuroimage</source> <volume>13</volume>: <fpage>920</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr52-0269881110379509">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallner</surname><given-names>M</given-names></name>
<name><surname>Hanchar</surname><given-names>HJ</given-names></name>
<name><surname>Olsen</surname><given-names>RW</given-names></name>
</person-group> (<year>2006</year>) <article-title>Low-dose alcohol actions on alpha4beta3delta GABAA receptors are reversed by the behavioral alcohol antagonist Ro15-4513</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>103</volume>: <fpage>8540</fpage>–<lpage>8545</lpage>.</citation>
</ref>
<ref id="bibr53-0269881110379509">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Wechsler</surname><given-names>D</given-names></name>
</person-group> (<year>1981</year>) <article-title>WAIS-R manual</article-title>. <publisher-loc>New York</publisher-loc>: <publisher-name>The Psychological Corporation</publisher-name>.</citation>
</ref>
<ref id="bibr54-0269881110379509">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Wechsler</surname><given-names>D</given-names></name>
</person-group> (<year>1987</year>) <article-title>The Wechster Memory Scale–revised</article-title>. <publisher-name>The Psychological Coporation, Harcourt Brace Jovanovich, Inc</publisher-name>.</citation>
</ref>
</ref-list>
</back>
</article>